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Abstract
Background: In order to confirm therapeutic effects of topiramate on posttraumatic stress
disorder (PTSD) observed in a prior study, a new prospective, open-label study was conducted to
examine acute responses in chronic, nonhallucinatory PTSD.
Methods: Thirty-three consecutive newly recruited civilian adult outpatients (mean age 46 years,
85% female) with DSM-IV-diagnosed chronic PTSD, excluding those with concurrent auditory or
visual hallucinations, received topiramate either as monotherapy (n = 5) or augmentation (n = 28).
The primary measure was a change in the PTSD Checklist-Civilian Version (PCL-C) score from
baseline to 4 weeks, with response defined as a ≥ 30% reduction of PTSD symptoms.
Results: For those taking the PCL-C at both baseline and week 4 (n = 30), total symptoms declined
by 49% at week 4 (paired t-test, P < 0.001) with similar subscale reductions for reexperiencing,
avoidance/numbing, and hyperarousal symptoms. The response rate at week 4 was 77%. Age, sex,
bipolar comorbidity, age at onset of PTSD, duration of symptoms, severity of baseline PCL-C score,
and monotherapy versus add-on medication administration did not predict reduction in PTSD
symptoms. Median time to full response was 9 days and median dosage was 50 mg/day.
Conclusions: Promising open-label findings in a new sample converge with findings of a previous
study. The use of topiramate for treatment of chronic PTSD, at least in civilians, warrants
controlled clinical trials.
Background
Posttraumatic stress disorder (PTSD) is a difficult-to-treat
condition that over a lifetime affects approximately 10%
of the general population [1]. The condition develops
after traumatic events such as combat, terror activities, dis-
aster, or rape, and has 3 main features: (1) reexperiencing
the trauma through recollection, dreams, and reliving, (2)
avoidance of thoughts, activities, and emotions associated
with the trauma, and (3) hyperarousal [2]. PTSD is usually
a chronic disorder, with one third of patients displaying
symptoms for ≥ 10 years after experiencing the traumatic
event [3,4]. Generally the response to pharmacotherapy
has been poor, with many patients completely unrespon-
sive and others only marginally responsive [5]. Some tri-
cyclic antidepressants, monoamine oxidase inhibitors,
and selective serotonin reuptake inhibitors have demon-
strated efficacy in double-blind trials [3]. The complex
neurobiology of PTSD involves a number of systems,
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including dopaminergic, serotonergic, sympathetic,
hypothalamic-pituitary-adrenal, and various anatomic
regions of the amygdala and other parts of the limbic sys-
tem [3]. It has been suggested that after traumatic events
limbic nuclei may become kindled or abnormally sensi-
tized [6], leading to increased susceptibility for psychic
and physical arousal and psychiatric disturbance [2].
Because of the suggested involvement of the kindling phe-
nomenon, several anticonvulsants have been assessed in
the treatment of PTSD, including carbamazepine, val-
proate, lamotrigine, gabapentin, tiagabine, and topiram-
ate [3].
Topiramate has a broad spectrum of pharmacologic prop-
erties, including Na+ channel blockade [7-11], inhibition
of some high voltage-activated Ca2+  channels [12],
enhanced γ-aminobutyric acid (GABA) neuroinhibition at
novel GABAA receptors [13,14], glutamate inhibition at
kainate and α-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) receptors [15,16], and promotion
of protein phosphorylation of neuronal conductance
channels [15]. These properties, together with inhibitory
activity in animal kindling models [17,18], suggest that
topiramate may have therapeutic potential in PTSD.
Treatment with topiramate has been reported to improve
reexperiencing symptoms associated with civilian PTSD
[6]. Results from that study, which included a number of
patients who were classified as treatment resistant, sug-
gested that topiramate fully or partially suppressed both
intrusions (distressing recollections or nonhallucinatory
flashbacks) and nightmares, if present, in 89% of patients
with nonhallucinatory PTSD.
Although the DSM-IV definition of PTSD lists hallucina-
tions among reexperiencing symptoms [19], because a
few patients displayed varying degrees of impaired reality
testing of hallucinations, it was difficult to determine if
hallucinations were due to PTSD, to an independent psy-
chotic disorder, or, in some individuals, to both.
Although psychotic variants of PTSD have been reported
in as many as 40% of veterans with chronic combat-asso-
ciated PTSD without evidence of a primary psychotic dis-
order [20,21], it is also possible for patients with
psychotic disorders to have comorbid PTSD, leaving ques-
tions about whether specific hallucinations should be
attributable to the PTSD reexperiencing cluster or to a psy-
chotic disorder. Because the prior study found a more
robust effect in the group of PTSD patients without hallu-
cinations [6], it was decided to focus further on the core
group of PTSD patients without ambiguous symptoms
confounded by the possible presence of independent psy-
chotic disorders.
Based on these earlier results of topiramate in PTSD, a
fully prospective open-label study was begun to see
whether the previously observed signal of a therapeutic
benefit of topiramate for chronic civilian PTSD could be
confirmed. None of the patients reported in the earlier
study were included in the present study. In order to
address methodological limitations of the prior study, the
current study is modified in 4 major ways: (1) it excludes
patients with hallucinations, (2) it limits the study to 12
weeks, (3) it prospectively employs the PTSD Checklist-
Civilian Version (PCL-C) as a validated clinical assess-
ment instrument in all patients, and (4) it determines a
clinical response rate as of week 4, using a conventional,
predetermined definition for positive response as a ≥ 30%
improvement in a standardized clinical rating scale.
Methods
This sample included all consecutive adults (n = 33) meet-
ing the DSM-IV criteria for chronic civilian PTSD in an
outpatient private practice who started open-label topira-
mate between January 2000 and November 2002 in the
course of clinical care. The study excluded patients with
concurrent auditory or visual hallucinations associated
with either PTSD or a possible psychotic disorder. Topira-
mate, administered either as monotherapy (n = 5) or
added to the patients' existing therapeutic regimen (n =
28) (Table 1), was initiated at a starting dosage of 12.5 to
25 mg/day and increased in 25- to 50-mg/day increments
every 3 to 4 days as tolerated until a clinical response was
achieved.
The study was performed according to the Declaration of
Helsinki. Each participant provided verbal informed con-
sent based on disclosure of off-label usage, the availability
of alternative medications for PTSD such as sertraline and
paroxetine, and expected adverse events and risks. Verbal
consent was deemed appropriate and sufficient because of
the nonexperimental nature of the treatment. Because this
was a descriptive study using aggregate data gathered in
the course of treating patients in clinical practice for their
own benefit and not an experimental design, there was no
protocol that required Institutional Review Board
approval. Patients were asked to measure their symptoms
using standardized clinical instruments already routinely
used as a part of individual care. The study included no
features of clinical studies, such as randomization, con-
cealment of treatment, or surrender of patient decision-
making rights, as an integral part of conducting the study.
The primary outcome was a change in PTSD symptoms
calculated from change in PCL-C score from baseline
through 4 weeks of treatment [22]. The PCL-C, a validated
self-report instrument, strongly correlates (k~0.90) with
the Clinician-Administered PTSD Scale (CAPS), a struc-
tured clinical interview widely used in PTSD studies [23].BMC Psychiatry 2004, 4:24 http://www.biomedcentral.com/1471-244X/4/24
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The PCL-C is scored on a Likert scale of 1 to 5 (1 = not at
all; 5 = extremely) for each of 17 items that cover all 3
symptom clusters (B, reexperiencing; C, avoidance/numb-
ing; D, hyperarousal), yielding a score range of 17 to 85.
A total score of ≥ 50 meets the threshold for active PTSD.
In accordance with conventional usage, a 30% reduction
in clinical symptoms of PTSD was defined as a positive
clinical response. The secondary measures included were
Cluster B symptoms of reexperiencing of trauma, includ-
ing trauma-related intrusions and nightmares. Secondary
measures were limited to Cluster B symptoms because of
the practical difficulty patients in clinical practice can have
linking a symptom (such as avoidance, numbing, hypera-
rousal, insomnia, or startling) specifically to a trauma as
opposed to some other source, as required by the DSM-IV
definitions. Also, Cluster B symptoms appeared to be
among the most distressing and salient for many patients,
thereby making tracking these distinctive symptoms com-
paratively easy.
Data on patient demographics, concomitant medication,
comorbidities, primary trauma, and duration of PTSD
were collected at baseline. Assessments were made
through clinical interviews over a 12-week period. Cessa-
tion of reexperiencing symptoms was considered partial if
subjects reported a definite reduction in intensity and fre-
quency of nightmares or intrusive recollections or flash-
backs. Full cessation was defined as complete elimination
of nightmares and intrusions for a sustained period.
Adverse effects were recorded if they resulted in treatment
discontinuation.
Statistical analyses were performed using Jandel SigmaS-
tat®  Version 2.0 (Jandel Corporation, San Rafael, CA,
USA). A single paired t-test of before and after total PCL-C
scores was used to analyze the data. Subscale scores for
PCL-C Clusters B, C, and D were also evaluated.
Results
Patient characteristics
Baseline patient characteristics and concomitantly admin-
istered medications are listed in Tables 1 and 2, respec-
tively. All monotherapy patients were in the nonbipolar
subgroup. Primary traumas for which symptoms were
reported are detailed in Table 3. Of these, 9 were of child-
hood onset, with 4 involving childhood physical assault,
3 unwanted sex or sexual assault, and 2 sudden unex-
pected or violent deaths.
Primary measures
Reduction in PCL-C symptoms
Ninety-one percent of patients (30/33) with baseline PCL-
C measurements completed a PCL-C at week 4. In those
patients, the total score was 62.6 at baseline and 40.3 at
week 4. In addition, the scores for reexperiencing,
avoidance, and hyperarousal clusters were 18.2, 25.1, and
19.2 at baseline and 11.2, 17.2, and 12.3 at week 4,
respectively. To calculate percentage reduction in PTSD
symptoms, to correct for an absence of symptoms being
scored as "1" for each item, the change in score between
baseline and week 4 was divided by the baseline score
minus the minimum score for no symptoms. Therefore,
the change in total symptoms was calculated as (baseline
– week 4)/(baseline – 17). Total symptoms declined sig-
nificantly (49%) by week 4 (paired t-test, P < 0.001). In
addition, subscale symptoms for reexperiencing (Cluster
B), avoidance/numbing (Cluster C), and hyperarousal
(Cluster D) decreased by 53%, 43%, and 48%, respec-
tively, from baseline (Figure 1). By the end of week 4, 70%
of all entrants in the study (n = 33) and 77% of those with
both baseline and week 4 PCL-C scores (n = 30) were pos-
itive responders, defined as a ≥ 30% improvement in
symptoms.
Predictors of reduction in PCL-C symptom improvement
Comparisons for bipolar versus nonbipolar patients (50%
versus 49%, analysis of variance [ANOVA]), duration of
symptoms (r = 0.37), age at onset of PTSD (r = -0.36),
severity of baseline PCL-C score (r = 0.02), age (r = -0.02),
female sex (49% versus 50%, ANOVA), and monotherapy
versus add-on medication administration (53% versus
48%, ANOVA) found none significantly associated with
reduction in PCL-C symptoms.
Secondary measures
Results for combined suppression of nightmares and intrusions are 
shown in Table 4
Of the 33 patients who entered the study, 79% fully
ceased having reexperiencing symptoms with a mean time
Table 1: Patient characteristics
All subjects N = 33
Mean age, years ± SD 46 ± 6.5
Range 29–55
Sex, %
Women 85
Men 15
Mean age at onset of PTSD, years ± SD 29 ± 15
Range 2–53
Mean duration of PTSD history, years ± SD 18 ± 15
Range 0–46
Patients with comorbid disorders, N (%)
Bipolar disorder 10 (30)
Major depressive disorder 21 (64)
Substance abuse
Current 3 (9)
In past 5 (15)
SD =standard deviation; PTSD = posttraumatic stress disorder.BMC Psychiatry 2004, 4:24 http://www.biomedcentral.com/1471-244X/4/24
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to full cessation of 15 days. The onset of full cessation for
all patients occurred at ≤ 200 mg/day and the onset of par-
tial cessation for all patients at ≤ 50 mg/day. Ninety-four
percent of patients with nightmares and 79% of patients
with intrusions at baseline reported full cessation at the
end of week 4.
Discontinuations
Serious adverse events
There were no serious adverse events during this study. Of
the 33 patients who entered the study, 7 (21%) discontin-
ued due to adverse events and 5 (15%) for other reasons.
The single most common adverse event resulting in
discontinuation was intolerable nervous system overstim-
ulation (panic/nervousness/overstimulation/ shakiness),
reported by 3 patients. Other adverse events resulting in
discontinuation included clumsiness (n = 2), cognitive
impairment (n = 1), and severe headache (n = 1). Addi-
tional reasons for discontinuation included personal
choice (n = 1) and lack of relapse of PTSD symptoms after
Table 2: Concomitant medications
Medication type Number of patients (N = 33)
SSRIs 12
Benzodiazepines 10
Stimulants 6
Atypical neuroleptics 3
Gabapentin 3
Lamotrigine 5
Mirtazapine 3
Venlafaxine 3
Verapamil 1
Other 8
Monotherapy 5
SSRIs = selective serotonin reuptake inhibitors.
Table 3: Primary traumas
Trauma type Number of patients, 
N = 33
Unwanted sex 11
Physical assault 6
Sudden violent death 4
Sudden unexpected death of loved one 3
Sexual assault 2
Fire/explosion 1
Weapon assault 1
Combat 1
Life-threatening illness 1
Other 3
Mean percentage symptom reduction at week 4 Figure 1
Mean percentage symptom reduction at week 4. 
Symptom reduction in those 30 subjects who completed a 
PCL-C at baseline and after 4 weeks. *Paired t-test, P < 0.001 
versus baseline. PTSD = posttraumatic stress disorder; PCL-
C = PTSD Checklist-Civilian Version.
Table 4: Secondary efficacy measures
Combined suppression of nightmares and intrusions
Responder status, n (%)
Full 26/33 (79%)
Partial 3/33 (9%)
None 4/33 (12%)
Mean time to response, days ± SD, (range)
Full response (n = 25) 15 ± 18 (1–83)
Partial response (n = 17) 11 ± 13 (2–46)
Median time to full response, days 9
Median time to partial response, days 5
Mean dosage at time of response, mg/day
Full response 60 ± 47
Partial response 32 ± 15
Median dosage at time of response, mg/day
Full response 50
Partial response 25
Modal daily dosage for full response, mg/day 25
% of patients in the 12.5–50-mg/day range 65
Modal dosage at time of partial response, mg/day 25
% of patients in the 12.5–50-mg/day range 100
Improvements in nightmares
Full cessation of nightmares 17/18 (94%)
Improvements in intrusions
Full cessation of intrusions 26/33 (79%)
Partial improvement 3/33 (9%)
No improvement 4/33 (12%)
SD = standard deviation.
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interrupting medication (n = 4). Of the 12 patients that
discontinued, 54% (n = 7) fully ceased having reexperi-
encing symptoms of nightmares/intrusions and 15% (n =
2) partially ceased having reexperiencing symptoms of
nightmares/intrusions. The median time to termination
was 25.5 days (range, 4–77).
Predictors of discontinuation
There were no statistically significant predictors of panic-
like adverse events resulting in discontinuation from the
study (age, sex, symptom duration, age at onset, bipolar-
ity, substance abuse, baseline severity of illness), although
the coadministration of a benzodiazepine nearly reached
significance (Fisher exact test, P = 0.05). No monotherapy
patients discontinued because of overstimulation/panic-
like responses, so the possibility of drug interactions or
conditions such as comorbid panic disorder contributing
to this reaction should be considered in future
investigations.
Discussion
Results of this prospective open-label study suggest that
the use of topiramate for the treatment of chronic PTSD in
civilians is indeed promising and warrants controlled clin-
ical trials. Topiramate was able to improve symptoms of
reexperiencing, avoidance, and hyperarousal by 49%
overall, compared with baseline, and decreased intrusions
in 94% of patients and nightmares in 79% of those with
this symptom.
Although there are numerous other reports describing the
use of antiepileptic agents for the treatment of PTSD, most
are case reports and case series, and some lack the use of
standardized PTSD scales. The first published trials using
anticonvulsants date back almost 20 years, when a 5-week
trial of carbamazepine in 10 combat veterans produced a
36% reduction in a nonvalidated interviewer-scored
instrument [24]. Studies on adjunctive therapy with val-
proate reported improved global scores in avoidance and
hyperarousal, but not reexperiencing symptoms in veter-
ans over a 14-month period [25], whereas a subsequent 8-
week open-label trial reported a small, 17% reduction in
CAPS score in 13 subjects with significant reductions in all
3 cluster criteria [26]. Two studies in which valproate was
used as monotherapy reported varying results, with one
showing a 30% reduction in total CAPS scores in 28 veter-
ans [27], whereas the other in 10 civilian patients with
non-combat-related PTSD showed no improvement
[28].The only double-blind placebo-controlled trial eval-
uating an anticonvulsant in PTSD was conducted with
lamotrigine [29]. Overall, after 10 weeks of treatment, 5 of
10 subjects were characterized as responders, compared
with 1 of 4 subjects receiving placebo. However, a last
observation carried forward analysis revealed only a 23%
decrease in mean pretreatment scores with lamotrigine,
compared with 20% in the placebo group. A retrospective
clinical series of adjunctive gabapentin therapy in 30 con-
secutive patients with PTSD assessed improvement of tar-
get symptoms such as nightmares, insomnia, and
irritability. It was reported that the majority of patients
(77%) showed moderate or greater improvement in dura-
tion of sleep, and most notably a decrease in the
frequency of nightmares [30]. These studies highlight the
need for double-blind placebo-controlled trials using
standardized and validated questionnaires.
It is encouraging that the results of this current study with
topiramate were consistent with the earlier, preliminary
data obtained in patients with PTSD. Percentage respond-
ers (77% versus 75%), median time to full response (9 d
versus 8 d), suppression of intrusions and nightmares
(88% versus 89%), and discontinuation rate (39% versus
32%) were all similar. Overall, the open-label experience
with topiramate, based on patient statements and self-rat-
ing reports, suggests that the drug may have a rapid rate of
response with limited risk of clinically significant adverse
events and no evidence of tolerance developing over time
[6,31]. Moreover, from topiramate studies in epilepsy
[Topamax prescribing information] it is known that the
drug is not associated with the cardiac, pancreatic, and
hematologic toxicity found with valproate or car-
bamazepine [3]. In addition, topiramate is not associated
with weight gain, a side effect reported with valproate that
can predispose patients to diabetes mellitus [32]. Topira-
mate also offers potential clinical advantages over serot-
onin reuptake inhibitors (SSRIs) because it does not
appear to destabilize mood in patients with comorbid
bipolar disorder and is relatively devoid of common
adverse effects of SSRIs, such as sexual dysfunction, weight
gain with chronic use, or sedation when used as
monotherapy.
Limitations of the present study include: (1) the absence
of structured assessment data following week 4 to test the
maintenance of response over time, (2) use of self-report
instruments that, although validated and correlated with
results of structured clinical interviews, may be less accu-
rate than structured interviews, and (3) the absence of
clinical assessment scores at the time patients discontin-
ued the trial. From a broader perspective, the greatest lim-
itation of this study is characteristic of all open trials: the
lack of standard features of clinical trials such as placebo
controls, randomization, and blinding of raters.
Conclusions
Fundamentally, the findings of current and prior topiram-
ate studies are convergent and consistently signal a poten-
tially beneficial therapeutic effect for all 3 criteria clusters
of chronic PTSD in civilian adults. In both studies, there is
a positive response in a large proportion of patients, atBMC Psychiatry 2004, 4:24 http://www.biomedcentral.com/1471-244X/4/24
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dosages considerably below the usual anticonvulsant dos-
age levels of 200 to 600 mg/day, and a rapid onset. The
effect appears independent of comorbidity with bipolar
disorder, age, sex, duration of symptoms, baseline severity
of illness, or administration alone or with other psycho-
tropic medications. The purpose of this study was to pro-
spectively test the results of an earlier open-label trial in a
new sample; however, the limitations of those open stud-
ies will have to be addressed in double-blind, placebo-
controlled studies, which are currently in progress.
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